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Background: Pain is a negative factor in the recovery process of postoperative patients, causing pulmonary
alterations and complications and affecting functional capacity. Thus, it is plausible to introduce transcutaneous
electrical nerve stimulation (TENS) for pain relief to subsequently reduce complications caused by this pain in the
postoperative period. The objective of this paper is to assess the effects of TENS on pain, walking function,
respiratory muscle strength and vital capacity in kidney donors.
Methods/design: Seventy-four patients will be randomly allocated into 2 groups: active TENS or placebo TENS. All
patients will be assessed for pain intensity, walk function (Iowa Gait Test), respiratory muscle strength (maximal
inspiratory pressure and maximal expiratory pressure) and vital capacity before and after the TENS application. The
data will be collected by an assessor who is blinded to the group allocation.
Discussion: This study is the first to examine the effects of TENS in this population. TENS during the postoperative
period may result in pain relief and improvements in pulmonary tests and mobility, thus leading to an improved
quality of life and further promoting organ donation.
Trial registration: Registro Brasileiro de Ensaios Clinicos (ReBEC), number RBR-8xtkjp.
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Respiratory function testsBackground
Organ donation has grown exponentially in Brazil, which
is directly reflected by the significant increase in the
number of transplants. A successful transplant affects
both the lifespan and quality of life of patients. A renal
graft from a living donor provides a 10 to 12% better
chance of survival at one year [1]. There are several
methods used to remove a kidney, and all are designed
to minimize the harm to the donor. Methods that have
been used since 1995 include lumbotomy, the subcostal
access route and laparoscopic access routes [2-4].* Correspondence: liebano@gmail.com
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reproduction in any medium, provided the orThe postoperative complications in patients who under-
went nephrectomy can be divided into mechanical, pul-
monary, vascular and operative wounds [5]. The major
pulmonary complications during this period included the
following: atelectasis, pneumothorax, pulmonary conges-
tion, pneumonia and hypoxemia [6]. Pain is another factor
that negatively influences the postoperative outcomes of
patients, even with the administration of analgesics,
including the most widely used opioids [7]. The major
difficulty when using opioids is calculating the minimum
concentration for effective analgesia, as overuse can lead
to cough suppression, can limit effective sputum expulsion
and can cause dizziness, nausea, vomiting, sedation, urin-
ary retention and constipation, which are known side. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pharmacological methods of pain control can help limit
the use of opioids and reduce side effects [7].
Transcutaneous electrical nerve stimulation (TENS) is
considered to be a non-pharmacological intervention
strategy used for physical therapy pain relief with min-
imal side effects [9]. The use of TENS activates opioid
receptors, which reduce the activation of the nociceptive
sensory pathways and provide pain relief [10-12]. TENS
has been used as a therapeutic option to control chronic
and acute pain since the early 1970s. Its postoperative
use following cardiac and thoracic surgery provides
decreased analgesic consumption, lower incidence of
pulmonary complications (such as atelectasis) and im-
proved pulmonary function [13,14]. However, the posi-
tive effects of TENS have not been consistent. Some
researchers found that TENS was not effective in all
patients, especially those with more severe postoperative
pain. Additionally, the declines in lung function and ven-
tilation did not always responded positively after the use
of TENS. Therefore, the actual role of TENS in control-
ling postoperative pain and its consequences remains
controversial [6,13,15].
There has been a significant increase in the rate of kid-
ney transplants performed using living donors in recent
years, raising questions regarding the short- and long-
term effects of this procedure, such as whether there
would there be a difference in pain intensity or changes
in pulmonary function and donor independence or func-
tionality in the postoperative period after the use of
TENS. Moreover, no previous studies were found in the
literature that investigated the effects of TENS in this
population. For these reasons, we decided to conduct a
prospective randomized controlled study to follow kid-
ney donors who underwent lumbotomy or subcostal
nephrectomy to evaluate the effect of TENS on pain,




This study is a prospective randomized controlled and
double-blind. Seventy-four patients will be randomly
distributed into two groups: active TENS + analgesics
(n = 37) and placebo TENS + analgesics (n = 37).
Randomization will be performed by an investigator not
involved in data collection using the sequentially
numbered, opaque sealed envelopes (SNOSE) allocation
concealment method [16,17]. Patients will be admitted
one day before surgery and will undergo group ran-
domization on the first day of the postoperative period.
After randomization, the patients will be assessed for pain
intensity, respiratory muscle strength, vital capacity and
walking function before and after the use of TENS. Thepresent study was approved by the Research Ethics
Committees of University of the City of Sao Paulo and
Federal University of Sao Paulo. All participants will
receive written and verbal information on the aims and
procedures of the study and will sign a consent form to
agree to participate in the study.
All patients will be advised on the assessments that
will be performed, including general information on the
surgical procedure (type and size of the incision, sed-
ation, intubation and need for admission to the Intensive
Care Unit). The study flow diagram is presented in
Figure 1.
Participants
This study will be conducted in the Kidney and Hyper-
tension Hospital - Oswaldo Ramos Foundation, a supple-
mentary service of the Federal University of Sao Paulo.
The study will include 74 living kidney donors who
underwent nephrectomy performed by two approaches:
lumbotomy and the subcostal route. The route choice is
dependent on the team performing the procedure, and
these teams operate alternately on weekdays.
Inclusion criteria
 All living kidney donors undergoing nephrectomy by
lumbotomy or the subcostal route;
 At least 18 years old and of either sex;
 Without acute or chronic pulmonary disease;
 Ability to perform the necessary physiotherapy
maneuvers and measures;
 Pain intensity at rest greater than or equal to 2 and less
than or equal to 7 on a numeric rating scale (0–10)
Exclusion criteria
 All living kidney donors who have previous
experience with TENS;
 Need for surgical intervention on another organ in
addition to the kidney;
 Surgical reintervention during the data collection
period;
 Required mechanical ventilation for more than
12 hours;
 Died within 6 hours of the operation
Intervention
Application of active TENS
The use of active TENS will be conducted with a Neurodyn
Portable TENS unit (IBRAMED) with two channels. The
generator emits asymmetric, balanced, biphasic pulses.
Two self-adhesive electrodes (VALUTRODE - 9 × 5 cm)
will be placed in parallel on both sides of the incision with
a 3-cm distance between them. The duration of the TENS
Figure 1 Study flow diagram of the randomized controlled trial.
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pulse duration of 100 microseconds [18]. The intensity
(amplitude) will be increased until the patient is able to
feel a strong but comfortable tingling sensation. Patients
will be asked about the intensity of the TENS every 10 -
minutes. In the case of sensory habituation, the amplitude
will be increased until the individual again feels a strong
but comfortable tingling sensation. The application will be
performed on the first day of the postoperative period.
Application of placebo TENS
The use of the placebo TENS will be performed with an ap-
paratus identical in appearance to the active TENS
(Neurodyn Portable TENS, IBRAMED) that is specially
designed for this study. The device remains active only
during the first 30 seconds of application. After the initial
30 seconds, the current amplitude will gradually decrease
over 15 seconds until it reaches the zero value, thereby
interrupting the emission of electric current. The unit will
remain inactive for the rest of the application [19]. The
placebo TENS device displays a light during the entire ap-
plication, indicating to the patient that the device is active.
Patients will be informed that TENS may cause a slight
tingling sensation or no sensation during the procedure.They will be asked every 10 minutes about the inten-
sity of TENS, reinforcing the idea that lack of sensation
occurs in most cases due to habituation to the electric
current. Patients will be observed throughout the admin-
istration of TENS [20]. The mode of application of the
electrodes and the duration of the placebo TENS will be
the same as described in the active TENS.
Outcome measures
Primary outcome: pain intensity To evaluate pain in-
tensity, an 11-point numeric rating scale (NRS) will be
used, where 0 represents no pain and 10 represents the
most intense pain imaginable. The assessment will be
conducted at rest, during coughing and during respira-
tory tests (maximal inspiratory and expiratory pressures
and vital capacity) and walking function (Iowa Gait Test)
before and after administration of TENS [21].
Secondary outcomes: respiratory muscle strength, vital
capacity and walk function Patients will be assessed for
their respiratory muscle strength (maximal inspiratory
pressure (PImax), maximal expiratory pressure (PEmax))
and vital capacity (VC). PImax and PEmax will be
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an operating range of 300 cmH2O (calibrated before
each use) and with the patient in the seated position
with relaxed arms and a disposable mouthpiece and
nasal opening for the air leak.
To measure the inspiratory muscle strength (PImax),
the patient will be asked to perform a maximal expir-
ation to the level of residual volume (RV) and then per-
form a maximal inspiratory effort, which must be
maintained for approximately one second. To measure
expiratory muscle strength (PEmax), the patient will be
asked to perform a maximal inspiration at the level of
total lung capacity (TLC) and then perform a maximal ex-
piratory effort, which must be maintained for approxi-
mately one second [19,22,23]. The patient will be
encouraged by the evaluator during these procedures to
exert his/her maximal effort. The greatest of three con-
secutive measurements will be used. The mouthpieces
used to record respiratory muscle strength have a small
opening (± 2 mm) to exclude the force of the facial
muscles and make the measurements more reliable.
The vital capacity (VC) will be measured with a spir-
ometer (Wright Mark 8) with the patient in a seated
position and connected to a disposable mouthpiece and
nose clip to prevent air leakage. The test starts with in-
spiration to TLC, followed by expiration to the RV. The
greatest of three consecutive measurements will be
considered [19,22,23].
Assessment of walking function will be performed
using the Iowa Gait Test. Patients will be assessed on
three items: walking speed, distance travelled and level
of assistance while walking for 15 seconds [24]. The
evaluator will walk alongside the patient and measure
time using a digital timer (Oregon SL 110). The evalu-
ator will not talk during the test to allow the patient
to determine his/her own pace and will provide the
necessary assistance to the patient when needed. The
starting point will be marked with tape, and the pa-
tient will be instructed to walk forward as fast and
safely as possible and stop when requested. The place
where the patient stops will also be marked with tape,
and the distance between the two points marked will
be measured. Those who cannot walk independently will
receive assistance. The levels of assistance will be classified
as follows:
 Independent, no assistance
 Minimal assistance, one point of contact
(e.g., holding an arm)
 Moderate assistance, two points of contact
(e.g., holding both arms)
 Maximum assistance, three or more points of
contact (e.g., holding an arm and both hands at
the waist)The saturation of peripheral oxygen (SpO2) will be
monitored through a pulse oximeter (Nonin Onyx 9500)
to ensure proper oxygen saturation during the test. If
the SpO2 drops below 92% or 10% of the baseline, the
test will be stopped.
Procedure
Active TENS group
Patients in this group will receive prescription pain
medication for pain control. In addition to primary care,
patients will undergo TENS on the first day of the
postoperative period, with an exposure time of 1 hr. Pain
intensity, pulmonary tests and walking function will be
evaluated before and after the intervention with TENS,
immediately before the TENS is discontinued.
Placebo TENS group
Patients in this group will also receive prescription of
analgesics for pain control. Patients will undergo the same
procedures as the TENS active group, but the unit will
emit electrical current only during the first 30 seconds of
the application. One hour after the commencement of the
intervention, patients will be subjected to the same tests
as described above.
Blinding
Two assessors will be involved in the study and will be
trained to perform the procedures in this study. Assessor
1 will be responsible for the evaluation of pulmonary
tests, walking ability and assessment of pain intensity in
all patients in the study. Assessor 2 will be responsible
for administering TENS in all patients in the study. Only
Assessor 2 will know if the patient received the active or
placebo TENS. Both Assessor 1 and the patients will be
blinded to the mode of application of TENS. Assessor 2
will instruct patients not to report their perceptions dur-
ing the TENS administration to the assessor conducting
the assessments.
Data analysis
The sample size was calculated considering a difference
of two points in the verbal numeric pain scale between
the TENS active and placebo groups and an estimated
standard deviation of 3 based on data from a previous
study [25]. For a significance level of 0.05 and 80% power,
it was estimated that 37 participants would be required in
each group (Minitab, v.15, State College, PA).
The statistical analysis will be performed on an intent-
to-treat basis. The effects of the intervention on pain in-
tensity, pulmonary function, and walking capacity, will
be calculated using independent samples t tests for
normally distributed data. Data not normally distributed
will be compared using Mann–Whitney U tests. The
level of significance will be set at α = .05. The data will
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Chicago, IL) by an investigator who is blind to group
allocation.Discussion
The use of TENS during the postoperative period has
become more common in various types of surgery in re-
cent decades [13,14,26,27]. The postoperative benefits of
TENS exceed pain relief and include decreased analgesic
consumption, deceased incidence of pulmonary com-
plications (such as atelectasis) and improved pulmonary
function [6,8,13,14,28]. Several authors have evaluated
the postoperative effects of TENS following cardiac sur-
gery and found that TENS reduces pain and the amount
of analgesic consumption when compared to placebos or
controls [8,27,29].
An improvement in respiratory muscle strength and
increased pulmonary volumes and capacity, in addition
to a reduction of pain after the use of low-intensity
TENS was observed in the postoperative period of car-
diac surgery. This study also showed that the group that
underwent TENS experienced significant increases in
both PImax and PEmax compared to the control group
[6]. The effects of TENS on pulmonary function was
also assessed in 31 patients undergoing coronary artery
bypass grafting or valve replacement during the first 72
postoperative hours. Patients were randomly assigned to
two groups: TENS and placebo. As a result, an improve-
ment in the peak expiratory flow (PEF) values in the
group that underwent TENS was observed; however,
when both groups were compared, there were no signifi-
cant differences in the forced vital capacity (FVC) and
forced expiratory volume in 1 second (FEV1) values
[29]. Similar results were observed in a study of 45
patients in which TENS was used as a postoperative
complement to pharmacologic analgesia in patients
undergoing coronary artery bypass grafting. The authors
performed three spirometric measurements at 24, 48
and 72 hours after surgery and found that there were no
significant improvements in the spirometric values of
patients who were treated with TENS when compared
with those receiving the placebo treatment [14].
The use of TENS increases the analgesic effect in
patients undergoing a thoracotomy, providing an im-
portant analgesic strategy for the treatment of acute
postoperative pain [24,25,28,30,31]. However, a study
was conducted with 324 patients who underwent differ-
ent types of chest surgery and concluded that TENS had
little or no benefit after procedures associated with se-
vere pain (posterolateral thoracotomy) [26]. Accordingly,
the results after a lateral thoracotomy or sternotomy are
varied; many studies advocate the efficacy of TENS in
patients undergoing these surgeries, while others claimthat TENS has little or no value after these procedures
[26,32].
Here, we present the rationale and design for a ran-
domized controlled trial comparing the effects of active
TENS versus placebo TENS in patients undergoing
nephrectomy. This is the first study to be conducted on
the use of TENS in this population. The results of this
study will be published when it is completed.
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